Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.475 USD | +1.62% | +7.78% | -14.30% |
04-18 | Recursion Pharmaceuticals Insider Sold Shares Worth $367,007, According to a Recent SEC Filing | MT |
04-16 | Recursion Pharmaceuticals Names Najat Khan Chief R&D Officer | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.30% | 1.98B | |
-1.69% | 104B | |
+3.46% | 97.47B | |
+5.39% | 22.25B | |
-13.78% | 21.68B | |
-9.77% | 18.2B | |
-39.98% | 17.02B | |
-11.26% | 16.36B | |
+7.18% | 14.39B | |
+38.10% | 12.37B |
- Stock Market
- Equities
- RXRX Stock
- News Recursion Pharmaceuticals, Inc.
- Goldman Sachs Adjusts Recursion Pharmaceuticals' Price Target to $10 from $32, Keeps Neutral Rating